PEDIATRICS · 2022 · 25 citations · 30 references
MedicineNutritionPediatricsBreastfeedingMaternal NutritionNeonatologyCare Of Premature InfantsNeonatal DevelopmentNeonatal NutritionOmega-3 Fatty Acids In PregnancyPerinatal NutritionDocosahexaenoic AcidGestation PeriodMaternal Dietary SupplementationMaternal Fatty Acid NutritionMaternal Micronutrient SupplementationMaternal Omega-3 SupplementationPlacebo ComparatorsPreterm Birth Neurodevelopment
OBJECTIVES: To determine whether maternal supplementation with high-dose docosahexaenoic acid (DHA) in breastfed, very preterm neonates improves neurodevelopmental outcomes at 18 to 22 months' corrected age (CA). METHODS: Planned follow-up of a randomized, double-blind, placebo-controlled, multicenter trial to compare neurodevelopmental outcomes in breastfed, preterm neonates born before 29 weeks' gestational age (GA). Lactating mothers were randomized to receive either DHA-rich algae oil or a placebo within 72 hours of delivery until 36 weeks' postmenstrual age. Neurodevelopmental outcomes were assessed with the Bayley Scales of Infant and Toddler Development third edition (Bayley-III) at 18 to 22 months' CA. Planned subgroup analyses were conducted for GA (<27 vs ≥27 weeks' gestation) and sex. RESULTS: Among the 528 children enrolled, 457 (86.6%) had outcomes available at 18 to 22 months' CA (DHA, N = 234, placebo, N = 223). The mean differences in Bayley-III between children in the DHA and placebo groups were -0.07 (95% confidence interval [CI] -3.23 to 3.10, P = .97) for cognitive score, 2.36 (95% CI -1.14 to 5.87, P = .19) for language score, and 1.10 (95% CI -2.01 to 4.20, P = .49) for motor score. The association between treatment and the Bayley-III language score was modified by GA at birth (interaction P = .07). Neonates born <27 weeks' gestation exposed to DHA performed better on the Bayley-III language score, compared with the placebo group (mean difference 5.06, 95% CI 0.08-10.03, P = .05). There was no interaction between treatment group and sex. CONCLUSIONS: Maternal DHA supplementation did not improve neurodevelopmental outcomes at 18 to 22 months' CA in breastfed, preterm neonates, but subgroup analyses suggested a potential benefit for language in preterm neonates born before 27 weeks' GA.
30
Alan H. Jobe, Eduardo Bancalari · American Journal of Respiratory and Critical Care Medicine · 2001 · 4.8K citations
Medicine, Child Health, Pediatrics +15
Neonatal Necrotizing Enterocolitis
Martin Bell, Jessie L. Ternberg, Ralph D. Feigin et al. · Annals of Surgery · 1978 · 3.5K citations · Full text
Medicine, Microbiology, Pediatrics +12
Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid
Robert A. Gibson, Andrew J McPhee, Carmel T Collins et al. · JAMA · 2009 · 380 citations
Fatty acid utilization in perinatal de novo synthesis of tissues
M T Clandinin, J.E. Chappell, T Heim et al. · Early Human Development · 1981 · 272 citations